Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.
OBJECTIVE: Epidemiological studies have shown an increased risk for prostate carcinoma in men with serum IGF-I in the upper part of the age-related reference range. Recombinant human GH (rhGH) is widely used in patients with GH deficiency, usually raising the serum IGF-I levels into the normal range...
主要な著者: | le Roux, C, Jenkins, P, Chew, S, Camacho-Hübner, C, Grossman, AB, Besser, G, Monson, J |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2002
|
類似資料
-
Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
著者:: Drake, WM, 等
出版事項: (1998) -
Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
著者:: Agha, A, 等
出版事項: (2007) -
Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy.
著者:: Colson, A, 等
出版事項: (2008) -
Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
著者:: Florakis, D, 等
出版事項: (2000) -
Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
著者:: Chung, T, 等
出版事項: (2008)